Valacyclovir Use in Pregnancy
Yes, valacyclovir (Valtrex) can be taken during pregnancy, particularly for treating active herpes simplex virus (HSV) infections, and the FDA drug label confirms that clinical data over several decades have not identified a drug-associated risk of major birth defects. 1
Safety Profile
The FDA label for Valtrex explicitly states that clinical data over several decades with valacyclovir and its metabolite acyclovir in pregnant women have not identified a drug-associated risk of major birth defects 1. This is supported by:
Valacyclovir Pregnancy Registry data: Among 111 pregnancies exposed to valacyclovir, the occurrence of major birth defects was 3.9% (95% CI: 1.3-10.7%) across all trimesters, which is comparable to the general population background risk of 2-4% 1
Large Danish cohort study: Among 229 first-trimester exposures to valacyclovir, the adjusted prevalence odds ratio for major birth defects was 1.21 (95% CI: 0.56-2.62), showing no increased risk 2
Clinical Indications During Pregnancy
For HSV Infections
Acyclovir is preferred over valacyclovir for HSV treatment in pregnancy based on the available guideline evidence 3. The 1998 CDC guidelines specifically state:
- First clinical episode of genital herpes during pregnancy may be treated with oral acyclovir 3
- For life-threatening maternal HSV infections (disseminated infection, encephalitis, pneumonitis, hepatitis), IV acyclovir is indicated 3
- Routine suppressive therapy with acyclovir in pregnant women with recurrent genital herpes is not recommended, though some experts use it near term to reduce cesarean delivery rates 3
The 1999 USPHS/IDSA guidelines note that oral acyclovir prophylaxis during late pregnancy is controversial but may be indicated for patients with frequent, severe recurrences, with no pattern of adverse pregnancy outcomes reported 4
For CMV Prevention (Different Context)
While the question asks about valacyclovir generally, it's important to note that high-dose valacyclovir (8g/day) has been studied for preventing vertical transmission of cytomegalovirus (CMV), not HSV. This is a distinct indication with different dosing 5, 6.
Important Caveats and Monitoring
Renal Toxicity Risk
Approximately 1-2% of pregnant women taking valacyclovir may develop reversible acute kidney injury 7, 8. The FDA label notes that 1.71% experienced acute renal failure that resolved after discontinuation 1. This requires:
- Baseline renal function assessment
- Monitoring during treatment
- Immediate discontinuation if creatinine rises
Dosing Considerations
- Standard HSV treatment doses are safe; the FDA specifically warns that high doses of valacyclovir (8g/day) in immunocompromised patients have been associated with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura 3
- For standard HSV indications in pregnancy, typical therapeutic doses are used, not the high doses studied for CMV prevention
Timing Matters
The risk-benefit calculation depends on gestational age:
- Neonatal HSV transmission risk is highest (30-50%) when maternal infection is acquired near delivery 1
- Risk is only ~1-3% with recurrent herpes or infection acquired early in pregnancy 3
- This influences the urgency and approach to treatment
Practical Algorithm
For pregnant women with HSV:
Active first episode or severe recurrence: Treat with oral acyclovir (preferred based on guidelines) or valacyclovir (acceptable based on FDA safety data)
Life-threatening HSV disease: IV acyclovir is mandatory 3
Frequent severe recurrences: Consider suppressive therapy, particularly in late pregnancy, after discussing risks/benefits 4
Routine suppression for history of genital herpes: Not routinely recommended, though some experts use acyclovir starting at 36 weeks to reduce cesarean delivery rates 9
Bottom Line
Valacyclovir can be used in pregnancy when clinically indicated for HSV infections, with decades of safety data showing no increased risk of birth defects. However, acyclovir remains the first-line choice based on guideline recommendations and more extensive pregnancy experience 3, 4. Monitor renal function during treatment, and reserve therapy for clear clinical indications rather than routine suppression in most cases.